Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Ovarian Cancer

Medically integrated dispensing models enhance oral oncology drug education and improve compliance and patient monitoring.
New model aims to ease transition from fee-for-service to value-based cancer care delivery using an oncology medical home framework and performance-based reimbursement that includes monthly care management payments.
Incident cases of ovarian cancer differed little between ever users and never users of powder with no dose-response relationship.
Although performance category weightings remain unchanged from 2019, the Centers for Medicare & Medicaid Services has raised the bar for participating providers by increasing the performance threshold from 30 to 45 points in 2020.
The use of combination therapies in the first- and second-line settings for advanced ovarian cancer has the potential to improve patient outcomes.
Although federal reform efforts are likely to stall in the Senate, legislation prohibiting gag clauses, claw backs, and price spreading are being passed at the state level.
Patients and healthcare providers should be aware of the toxicities that may occur with the use of PARP inhibitors so that they can manage them appropriately.
Results from 3 clinical trials demonstrate the value of PARP inhibitors as first-line or maintenance therapies in patients with advanced ovarian cancer.
The Final Rule by the HSS means that manufacturers’ copay cards or coupons do not apply to a patient’s deductible or out-of-pocket maximum limits in certain situations, but further clarification is needed.
CMS approves changes allowing limited utilization management in protected classes of drugs. However, other proposed changes that would have further eroded patient access were not implemented.
Page 1 of 3
Results 1 - 10 of 23